Fed’s Powell opens door to potential rate cuts at Jackson Hole
In a challenging market environment, Stereotaxis Inc. (NYSE:STXS) stock has touched a 52-week low, dipping to $1.65. The medical technology company, known for its innovative robotic technologies for the treatment of cardiac arrhythmias, has faced significant headwinds over the past year. With a market capitalization of $143 million and annual revenue of $27 million, the company has seen its shares decline by 41% over the past year. According to InvestingPro analysis, the company’s overall financial health score is currently rated as WEAK. Investors have shown concern as the stock struggles to regain momentum, marking a concerning period for the company amidst a broader industry downturn. The current price level represents a critical juncture for Stereotaxis as it navigates through market pressures and aims to revitalize investor confidence. Despite current challenges, analysts maintain price targets between $4 and $5 per share. InvestingPro subscribers can access 7 additional key insights about STXS, including detailed valuation metrics and growth projections. Get the complete picture with the comprehensive Pro Research Report, part of the analysis available for 1,400+ US stocks.
In other recent news, Stereotaxis reported its fourth-quarter 2024 earnings, revealing a revenue of $6.3 million, which fell short of the $8.08 million forecast by analysts. The company also reported an earnings per share (EPS) of -$0.09, missing the expected -$0.06. Despite these challenges, the company experienced a 39% year-over-year increase in revenue for the quarter, driven by system revenue growth. Stereotaxis’ full-year revenue remained flat at $26.9 million, indicating ongoing challenges in sustaining growth. The company maintains a strong gross margin between 51% and 54%, with cash and equivalents at $12.4 million and no debt.
Stereotaxis is focusing on expanding its catheter portfolio and launching new products, with expectations of double-digit growth in 2025. The company anticipates system revenue of $2-3 million per quarter and recurring revenue starting at $5 million in Q1, growing to $7 million by Q4. In a significant development, Stereotaxis has gained support from NVIDIA (NASDAQ:NVDA), which spotlighted its advancements in surgical robotics at its GPU Technology Conference. This collaboration provides Stereotaxis with access to NVIDIA’s extensive software development resources, bolstering its efforts in integrating AI into its robotic systems.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.